6932.Two
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
Business. The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.19, indicating a conservative leverage position. However, the company reported a negative return on equity of -30.61% and a negative return on assets of -24.15%, reflecting poor profitability. The current ratio of 8.84 suggests strong short-term liquidity, but the operating cash flow of -50.84 million and free cash flow of -62.89 million indicate significant cash outflows.
Profitability metrics are well below industry norms, with the company posting a net loss of 67.23 million and an operating loss of 68.45 million. These figures highlight a significant underperformance relative to the industry's preferred metrics, which typically emphasize stable revenue growth and positive operating margins.
The company's revenue concentration is not disclosed in the available data, but the absence of segment-specific revenue breakdowns suggests a lack of diversification. This could pose a risk if the company's primary therapeutic area faces regulatory or market challenges.
Looking ahead, the company is expected to continue facing financial headwinds, with no clear indication of revenue growth in the current or next fiscal year. The negative operating and free cash flows suggest that the company may need to secure additional financing to fund operations, which could impact its long-term financial stability.
The risk assessment indicates a medium liquidity risk, primarily due to the company's negative operating cash flow and free cash flow. While the dilution risk is currently low, the company's financial position may change if it needs to raise capital through equity issuance. The absence of dilution sources in the available data suggests that the company has not disclosed any immediate plans for share issuance.
Recent events, including the latest financial filing, show a continued decline in financial performance. The company has not disclosed any material events or strategic initiatives that could reverse this trend. The lack of recent positive developments raises concerns about the company's ability to generate sustainable revenue and improve profitability.
- The company is experiencing significant financial losses, with a net loss of 67.23 million and an operating loss of 68.45 million.
- The company's capital structure is relatively conservative, with a low debt-to-equity ratio of 0.19.
- Profitability metrics are poor, with a negative return on equity of -30.61% and a negative return on assets of -24.15%.
- The company's liquidity position is strong in the short term, but its negative operating and free cash flows indicate ongoing financial challenges.
- The company's financial outlook is uncertain, with no clear signs of revenue growth or improved profitability in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 6932.TWO Market data — financials · 2026-05-27